• linkedin
  • Increase Font
  • Sharebar

    Role of blue light cystoscopy to detect bladder cancer

    Increased tumor detection, reduced recurrence/progression support its use in NMIBC patients

    Zachary L. Smith, MDZachary L. Smith, MD Norm D. Smith, MDNorm D. Smith, MD Section Editor Christopher M. Gonzalez, MD, MBASection Editor Christopher M. Gonzalez, MD, MBA

    Dr. Zachary Smith is a Society of Urologic Oncology fellow at The University of Chicago Medicine, Chicago. Dr. Norm Smith is professor of surgery/urology and co-director of urologic oncology at The University of Chicago Medicine, Chicago. Section Editor Christopher M. Gonzalez, MD, MBA, is professor and chairman of urology at University Hospitals Case Medical Center and Case Western Reserve University School of Medicine, Cleveland.


    Transurethral resection of bladder tumor (TURBT) is one of the most frequently performed procedures by urologists. However, for such a common procedure, rates of residual/understaged disease on restaging TURBT are startlingly high. Additionally, there remain high rates of persistent disease following intravesical therapy in those who did not receive a restaging TURBT. Both of these findings raise questions over the quality of TURBT many patients are receiving.

    Also see: Top 5 bladder cancer articles of 2017

    Accordingly, great effort has been put forth to develop more advanced techniques for the detection and eradication of tumors. Blue light cystoscopy (BLC) is one such technique, and carries many benefits over the historical standard of care, white light cystoscopy (WLC). Currently, the joint AUA and Society of Urologic Oncology (SUO) guidelines on nonmuscle-invasive bladder cancer (NMIBC) recommend offering BLC to all patients with NMIBC.

    How BLC works

    BLC involves instillation of a photosensitizer into the bladder prior to cystoscopy. This photosensitizer induces accumulation of protoporphyrins in rapidly proliferating cells (ie, malignant tumor cells). These protoporphyrins are then converted to photoactive porphyrins, which fluoresce red when illuminated with blue light (wavelength of 360–450 nm) (figure). Despite the multiple photosensitizing agents evaluated in clinical studies, the only agent currently approved for use in the United States by the FDA is hexaminolevulinate (HAL, marketed as Cysview).

    Improved detection of tumors

    Numerous clinical studies have exhibited significantly improved tumor detection rates with BLC. Meta-analyses and systematic reviews reveal a 7% to 29% increased rate of identifying small papillary tumors with BLC over WLC alone (Eur Urol 2013; 64:846-54; Eur Urol 2013; 64:624-38; Ther Adv Urol 2015; 7:339-50). The majority of increased detection of papillary lesions comes from Ta tumors, with minimal increased detection of T1 tumors (Ther Adv Urol 2015; 7:339–50).

    However, the increased detection is substantially improved with carcinoma in situ (CIS), with a 15% to 41% increased rate of detection over WLC alone (Eur Urol 2013; 64:846-54; Eur Urol 2013; 64:624-38; Ther Adv Urol 2015; 7:339-50; J Urol 2007; 178:68-73). Importantly, BLC should be used as an adjunctive technique to WLC—not a replacement—since up to 15% of CIS lesions may be seen on WLC but not BLC (J Urol 2007; 178:68–73).

    Next: Decreased tumor recurrence, progression


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available